Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Grace K. Dy(Roswell Park Comprehensive Cancer Center), Alex A. Adjei(Roswell Park Comprehensive Cancer Center)
Cited by 329
Related Papers
Early Clinical Development of ARQ 197, a Selective, Non–ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
|The Oncologist|2011|72
Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways
|British Journal of Cancer|2016|37